Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Parkinson Disease 4”

319 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 319 results

Post-approval studies (Phase 4)Study completedNCT04489888
What this trial is testing

Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10)

Who this might be right for
Squamous Cell Carcinoma of Head and Neck
Merck Sharp & Dohme LLC 101
Large-scale testing (Phase 3)Study completedNCT02819518
What this trial is testing

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)

Who this might be right for
Triple Negative Breast Cancer (TNBC)
Merck Sharp & Dohme LLC 882
Not applicableStudy completedNCT02572713
What this trial is testing

Systemic Synuclein Sampling Study (S4)

Who this might be right for
Parkinson's Disease
Michael J. Fox Foundation for Parkinson's Research 80
Large-scale testing (Phase 3)Study completedNCT04246177
What this trial is testing

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

Who this might be right for
Carcinoma, Hepatocellular
Merck Sharp & Dohme LLC 479
Testing effectiveness (Phase 2)Study completedNCT03037203
What this trial is testing

A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness

Who this might be right for
Excessive SleepinessParkinson Disease
Jazz Pharmaceuticals 66
Not applicableLooking for participantsNCT04724941
What this trial is testing

Prodromal Alpha-Synuclein Screening in Parkinson's Disease Study

Who this might be right for
Parkinson Disease
University Hospital Schleswig-Holstein 2,000
Large-scale testing (Phase 3)Study completedNCT04934722
What this trial is testing

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer
Merck Sharp & Dohme LLC 186
Not applicableStudy completedNCT03247387
What this trial is testing

EOnOff - D1 Extension

Who this might be right for
Parkinson Disease
Boston University 34
Testing effectiveness (Phase 2)Study completedNCT01370811
What this trial is testing

A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease

Who this might be right for
Sialorrhoea
Orient Pharma Co., Ltd. 24
Testing effectiveness (Phase 2)Study completedNCT01399905
What this trial is testing

High and Low Dose Carbidopa Treatment of Parkinson's Disease

Who this might be right for
Parkinson's Disease
Oregon Health and Science University 14
Testing effectiveness (Phase 2)Study completedNCT02674061
What this trial is testing

Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100)

Who this might be right for
Ovarian Neoplasms
Merck Sharp & Dohme LLC 376
Testing effectiveness (Phase 2)Looking for participantsNCT07252739
What this trial is testing

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

Who this might be right for
Malignant Neoplasm
Merck Sharp & Dohme LLC 130
Large-scale testing (Phase 3)Study completedNCT01905657
What this trial is testing

Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)

Who this might be right for
Non Small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC 1,034
Testing effectiveness (Phase 2)Looking for participantsNCT05319730
What this trial is testing

Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

Who this might be right for
Esophageal Squamous Cell Carcinoma
Merck Sharp & Dohme LLC 230
Early research (Phase 1)Study completedNCT02964013
What this trial is testing

Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001)

Who this might be right for
Neoplasms
Merck Sharp & Dohme LLC 474
Large-scale testing (Phase 3)Study completedNCT03976323
What this trial is testing

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

Who this might be right for
Carcinoma, Nonsquamous Non-small-cell Lung
Merck Sharp & Dohme LLC 1,003
Early research (Phase 1)Ended earlyNCT04000529
What this trial is testing

Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

Who this might be right for
Non-small Cell Lung CarcinomaHead and Neck Squamous Cell CarcinomaEsophageal SCC+2 more
Novartis Pharmaceuticals 122
Large-scale testing (Phase 3)Study completedNCT02358031
What this trial is testing

Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)

Who this might be right for
Recurrent Head and Neck CancerMetastatic Head and Neck Cancer
Merck Sharp & Dohme LLC 882
Large-scale testing (Phase 3)Active Not RecruitingNCT05239728
What this trial is testing

Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

Who this might be right for
Carcinoma, Renal Cell
Merck Sharp & Dohme LLC 1,800
Testing effectiveness (Phase 2)Active Not RecruitingNCT02628067
What this trial is testing

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Who this might be right for
Advanced CancerAnal CarcinomaAnal Cancer+22 more
Merck Sharp & Dohme LLC 1,609
Load More Results